BRAF and melanoma: To test the hypothesis that BRAF/MEK inhibitors could sensitize melanoma cells to MCL-1 inhibitors, we compared the effects of A1210477 given before versus after BRAF inhibitor treatment in A375M melanoma cells (Fig. 4f).